Evaluation of a Compliance Marker in Prescription Opioid Abusers With Chronic Pain
NCT ID: NCT02276989
Last Updated: 2017-02-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
PHASE2
INTERVENTIONAL
2014-12-31
2016-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Biomarkers of Injectable Extended Release Naltrexone Treatment
NCT02324725
Pain and Opioids: Integrated Treatment In Veterans
NCT04648228
Buprenorphine Combination Tablet Feasibility - 1
NCT00000298
Buprenorphine for Cancer Pain
NCT05910190
Pilot Trial of Opioid Taper Support
NCT01883882
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
1. We will examine the ability of two benign (in the doses used) medications, quinine (80mg) and acetazolamide (15mg) to serve as valid and reliable markers of medication use. The relative utility of each will be described for use with the study medication (PGB 400mg/day), a drug dependent on primarily renal excretion. In that both PGB and acetazolamide are eliminated unchanged in the urine, we will examine if the latter can be used without altering the elimination rate of the former, or whether a maker with both hepatic and renal modes of elimination (quinine) would serve as a better indicator of adherence in the trial.
2. Being a standard in clinical trials, the medication adherence marker riboflavin is used in the parent study (NCT01821430), as it can be readily detected in urine samples by simple visual inspection. However, riboflavin is a relatively gross indicator of medication use; it does not reside in the body for the time period typically required in outpatient trials, can be affected by dietary riboflavin and has variable absorption. Capitalizing on riboflavin's ease of detection, the second aim of this supplement will be to examine whether riboflavin when combined with one of the new candidate tracers, can provide a superior indicator of adherence, in that riboflavin can be qualitatively observed immediately, and the other tracer being quantitatively detected during subsequent urine toxicology analyses.
The cross over design of the study will allow us to address these aims in an efficient and straightforward manner. Following examination of the pharmacokinetics (PK) of PGB alone, it's PK will then be reexamined when compounded with acetazolamide, and again with both acetazolamide and riboflavin present. Next, after a short washout period, the studies PGB PK will be repeated with acetazolamide replaced by quinine. If the new tracers do not interfere with the PK of PGB, one of them will be chosen to be formulated (along with riboflavin) with PGB for use in the parent study, thereby providing both qualitative and quantitative indicators of adherence.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Compliance Intervention
Subjects will receive acetazolamide, quinine and riboflavin as experimental compliance markers and will serve as their own controls.
acetazolamide
On evening of Day 0, subjects will arrive at the session previously stabilized on buprenorphine and pregabalin. Pregabalin titration = 6 days prior to Day 0, during which time they will receive 100mg/day x 2 days, 200mg/day x2 days, and 300mg/day x 2 days, with the subjects receiving the full dose of 400mg/day beginning Day 0.
On Day 1, pregabalin PK measures will be collected.
On the mornings (8am) of Days 1 - 5, PGB compounded with the first tracer, ACZ will be administered.
On Day 5, subjects will again undergo PK testing on PGB + ACZ tracer.
On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.
On the mornings of Days 7-8 subjects will receive their PGB dose only.
Quinine
On the morning of Days 8-11, subjects will be administered the same dose of PGB, now compounded with the QUIN.
On Day 11, PK testing of QUIN and PGB will be repeated.
On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.
On Day 13 patients will be discharged with take-home doses of PGB that will taper to zero over the period of one week.
Riboflavin
All subjects will receive riboflavin on the following days of the study:
On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.
On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
acetazolamide
On evening of Day 0, subjects will arrive at the session previously stabilized on buprenorphine and pregabalin. Pregabalin titration = 6 days prior to Day 0, during which time they will receive 100mg/day x 2 days, 200mg/day x2 days, and 300mg/day x 2 days, with the subjects receiving the full dose of 400mg/day beginning Day 0.
On Day 1, pregabalin PK measures will be collected.
On the mornings (8am) of Days 1 - 5, PGB compounded with the first tracer, ACZ will be administered.
On Day 5, subjects will again undergo PK testing on PGB + ACZ tracer.
On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.
On the mornings of Days 7-8 subjects will receive their PGB dose only.
Quinine
On the morning of Days 8-11, subjects will be administered the same dose of PGB, now compounded with the QUIN.
On Day 11, PK testing of QUIN and PGB will be repeated.
On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.
On Day 13 patients will be discharged with take-home doses of PGB that will taper to zero over the period of one week.
Riboflavin
All subjects will receive riboflavin on the following days of the study:
On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.
On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. have medically diagnosed chronic pain condition,
3. be on a stable dose of buprenorphine (clinic modal dose),
4. history of prescription opioid abuse,
5. adequate venous access,
6. if female, a negative pregnancy test. Individuals will not be accepted who are unstable in buprenorphine treatment as evidence by continued illicit drug use and irregular clinic attendance in the previous trial,
7. be otherwise in good physical health or in care of a physician who is wiling to take responsibility for such treatment. The same conditions apply in cases of patients with a psychiatric disorder needing ongoing treatment.
Exclusion Criteria
2. significant ongoing medical problems (e.g., diabetes),
3. history of head injury or seizure,
4. serious psychiatric illness outside of drug use (e.g., schizophrenia),
5. recent use of any agent that inhibits or induces cytochrome P450 3A4 or 2D6,
6. nursing or pregnant female, or a female or male who does not agree to not become pregnant or father a child during the course of, and three months following completion of the study,
7. have a cardiac conduction or blood clotting disorder,
8. blood donation within the past 30 days prior to screening,
9. clinically significant laboratory results (as judged by the investigator/sub-investigator)
10. moderate to severe COPD,
11. renal impairment, and
12. severe renal hepatic impairment.
18 Years
50 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Georgetown University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Peggy Compton
Professor and Associate Dean
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Peggy Compton, RN, PhD
Role: PRINCIPAL_INVESTIGATOR
Georgetown University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Georgetown University
Washington D.C., District of Columbia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2013-0751
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.